

Emerging SARS-CoV-2 variants follow a historical pattern recorded in outgroups infecting non-human hosts

Kazutaka Katoh (✉ katoh@ifrec.osaka-u.ac.jp)

RIMD, Osaka University <https://orcid.org/0000-0003-4133-8393>

Daron M. Standley (✉ standley@ifrec.osaka-u.ac.jp)

RIMD, Osaka University

Short Report

Keywords: Molecular evolution, betacoronavirus

Posted Date: May 10th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-388200/v3>

License:   This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Emerging SARS-CoV-2 variants follow a historical pattern recorded in outgroups infecting non-human hosts

Kazutaka Katoh and Daron M. Standley

Research Institute for Microbial Diseases, Osaka University, 3-1 Yamadaoka, Suita 565-0871, Japan

April 23, 2021

Abstract

The ability to predict emerging variants of SARS-CoV-2 would be of enormous value, as it would enable proactive design of vaccines in advance of such emergence. Based on molecular evolutionary analysis of the S protein, we found a significant correspondence in the location of amino acid substitutions between SARS-CoV-2 variants recently emerging and their relatives that infected bat and pangolin before the pandemic. This observation suggests that a limited number of sites in this protein are repeatedly substituted in different lineages of this group of viruses. It follows, therefore, that the sites of future emerging mutations in SARS-CoV-2 can be predicted by analyzing their relatives (outgroups) that have infected non-human hosts. We discuss a possible evolutionary mechanism behind these substitutions and provide a list of frequently substituted sites that potentially include future emerging variants in SARS-CoV-2.

In December 2020, three SARS-CoV-2 variants emerged with increased infectivity from England, South Africa and Brazil. The fact that certain mutations in the spike (S) protein had occurred independently prompted us to reexamine our September 2020 study of the evolution of this protein [1]. In our original study, we characterized the *Importance* of each residue position in the S protein by comparing its diversity in SARS-CoV-2 with that in relatives (outgroups) that infected bats or pangolins by using a simple equation:

$$Importance = diversity(SARS-CoV-2 + outgroup) - diversity(SARS-CoV-2),$$

where $diversity(x)$ is defined as the number of different amino acids observed at the site in question in virus group x . This equation, which was meant to be descriptive rather than predictive, identified twenty positions of high *Importance*. We were thus surprised to find that, of these twenty positions, four were characteristic of the above emerging variants: Histidine 69, Valine 70, Glutamine 484 and Asparagine 501. These sites coincide with four out of the five residues (69, 70, 417, 484, 501) that have mutated independently in two or more of the three emerging lineages or the lineage transmitted between human and mink [2]. We reanalyzed the underlying sequence data and found that the *Importance* values of these sites were determined primarily by $diversity(outgroup)$, rather than $diversity(SARS-CoV-2)$. In hindsight, this is somewhat expected, as the latter term was close to unity at the time when we performed the analysis (i.e., before the emergence of new variants).

A natural question, then, is why a limited set of sites with high diversity in outgroups have also recently mutated in SARS-CoV-2. Two possible explanations are (i) neutral evolution, i.e., these sites are rapidly evolving under low functional constraints, and (ii) positive selection. The latter is more likely because the majority of the sites in question are estimated to have had more nonsynonymous substitutions than synonymous substitutions by Bayes Empirical Bayes analysis [3] applied to closely related outgroups (see the 4th column in <https://mafft.cbrc.jp/alignment/pub/sarscov2/fulllist.tsv>), although this estimation is sensitive to sequence selection. This observation suggests that adaptive evolution had occurred in outgroups at positions similar to those in SARS-CoV-2 infecting human [4]. This is also consistent with the recent report describing the possibility of adaptive evolution of the S protein in sea-




Figure 1: Diversity of the the S protein. For clarity, a single S protein is shown in the context of a spike trimer. **A**, **B**. *diversity(outgroup)*, the number of different amino acids observed at each site in outgroup, was computed using the original and broad definitions of outgroup: Low diversity (blue); High diversity (red). **C**. Emerging mutations are colored based on their frequency of appearance: 1 (green); 2 (red). **D**. Epitope frequency, the number of antibodies that contact each residue ($<6\text{\AA}$), was counted based on currently available Protein DataBank (PDB) entries of S protein-antibody complexes listed in <https://mafft.cbrc.jp/alignment/pub/sarscov2/epitopefrequency.txt>. 0 (blue); 15 (red). This value is not expected to represent all spike-targeting antibodies. **E**. Correspondence between *diversity(outgroup-original)* (**A**) and emerging mutations (**C**). **F**. Correspondence between *diversity(outgroup-broad)* (**B**) and emerging mutations (**C**). p values were calculated by Fisher's exact test under the null hypothesis that *diversity(outgroup)* (**A** or **B**) and distribution of emerging mutations (**C**) are independent of each other.

sonal coronaviruses [5]. Thus, a possible interpretation for the high diversity sites commonly observed in outgroups and SARS-CoV-2 is that these sites are involved in either infection of host cells, evasion of host immunity, or both.

Indeed, Glutamine 484 and Asparagine 501 are structurally close to the interface with the host cell receptor ACE2, which, in turn, is targeted by neutralizing antibodies. Histidine 69 and Valine 70, on the other hand, are far from the ACE2 binding site but proximal to a recently-reported epitope for infection-enhancing antibodies [6, 7]. The 69/70 deletion mutant also occurred in an immunosuppressed individual who underwent convalescent plasma therapy [8], suggesting that the mutation is a direct response to host antibodies. These two residues have also been reported to bind sialic acids [9]. Modification of these processes could thus enable the virus to escape from the host's immune system, albeit temporarily, as the change will inevitably be counteracted by a shift in the antibody repertoire of the host, resulting in an effective "arms race", reviewed in e.g., [10, 11]. In this scenario, the sites with higher diversity imply direct or indirect host-pathogen interactions and are thus in a constant state of flux.

According to this interpretation, it is possible that positions of mutations in future emerging variants can be predicted simply by identifying sites with high diversity in outgroups, where adversarial host-pathogen interactions have been occurring longer than for SARS-CoV-2 and humans.

Because of their potential importance in the design of vaccines against future emerging variants, we list residue positions with the highest *diversity*(outgroup) in Table 1, where we have considered two definitions of outgroups: one that is identical to that used in our original analysis in which 6 sequences were used and a broader definition (11 sequences) to increase the amount of data used in the calculation. Both datasets are available at <https://mafft.cbrc.jp/alignment/pub/sarscov2/>. When viewed as a heatmap on the spike molecular surface, it is apparent that the residue positions with high diversity are not evenly distributed, but form clusters in the N terminal domain (NTD), receptor binding domain (RBD) and S1/S2 cleavage site (Fig. 1A-D).

We note that the correspondence between the positions of emerging mutations and those with high *diversity*(outgroup) is significant by Fisher's exact test regardless whether the origi-

nal outgroup (Fig. 1E) or the broad outgroup (Fig. 1F) is used. Both the five positions (69, 70, 417, 484 and 501) observed in multiple emerging variants and the union of all variant positions were considered in calculating p . Mutations in the five positions are expected to continue to spread in humans as they are likely to affect interactions with host factors. The proposed simple method is suitable to predict such sites because they appear to be under positive selection in independent lineages. Consistently, the p values for the five positions are relatively low in panels E and F in Figure 1. There are some sites that have high diversity in outgroup but are not (yet) mutated in the current population of SARS-CoV-2, like the five positions before the emergence of new variants. Such sites are regarded to be mis-predicted in this statistical test, but may mutate in the future.

To anticipate new variants of SARS-CoV-2 as early as possible, a straightforward strategy would be to intensively collect a large amount of sequence data from human-infecting lineages [12]. Our observation above leads to a complementary strategy: prepare against new variants in advance by decoding the long history of host-pathogen interactions recorded in the outgroup sequences infecting non-human hosts. Unfortunately, currently efforts have focused almost exclusively on the former strategy and available outgroup sequences are limited. If richer sequence data of outgroups infecting bat, pangolin and other possible hosts becomes available, it would not only shed light on the origin of SARS-CoV-2 [13], but also give us an advantage in the arms race with this virus.

Conflicts of interest

None declared.

References


- [1] Saputri, D. S. et al. Flexible, Functional, and Familiar: Characteristics of SARS-CoV-2 Spike Protein Evolution. *Front. Microbiol.* 11: 2112 doi:10.3389/fmicb.2020.02112 (2020)

- [2] Lassaunière, R. et al. Working paper on SARS-CoV-2 spike mutations arising in Danish mink, their 2 spread to humans and neutralization data. https://files.ssi.dk/Mink-cluster-5-short-report_AFO2 (2021)
- [3] Yang, Z. et al. Bayes Empirical Bayes Inference of Amino Acid Sites Under Positive Selection. *Mol. Biol. Evol.* 22:1107-1118, doi:10.1093/molbev/msi097 (2005)
- [4] Tegally, H. et al. Detection of a SARS-CoV-2 variant of concern in South Africa. *Nature* doi:10.1038/s41586-021-03402-9 (2021)
- [5] Kistler, K. E. and Bedford, T. Evidence for adaptive evolution in the receptor-binding domain of seasonal coronaviruses OC43 and 229e. *eLife* 10:e64509, doi:10.7554/eLife.64509 (2021)
- [6] Li, D. et al. The functions of SARS-CoV-2 neutralizing and infection-enhancing antibodies in vitro and in mice and nonhuman primates. *bioRxiv* doi:10.1101/2020.12.31.424729 (2021)
- [7] Liu, Y. et al. An infectivity-enhancing site on the SARS-CoV-2 spike protein is targeted by COVID-19 patient antibodies. *Cell*, in press; *bioRxiv* doi:10.1101/2020.12.18.423358 (2020)
- [8] Kemp, S. A. et al. SARS-CoV-2 evolution during treatment of chronic infection. *Nature* 592:277-282, doi:10.1038/s41586-021-03291-y (2021)
- [9] Baker, A. N. et al. The SARS-COV-2 Spike Protein Binds Sialic Acids and Enables Rapid Detection in a Lateral Flow Point of Care Diagnostic Device. *ACS Cent. Sci.* 6:2046-2052, doi:10.1021/acscentsci.0c00855 (2020)
- [10] Meyerson, N. R. and Sawyer, S. L. Two-stepping through time:mammals and viruses. *Trends in Microbiology* 19:286-294, doi:10.1016/j.tim.2011.03.006 (2011)
- [11] Bonsignori, M. et al. Antibody-virus co-evolution in HIV infection: paths for HIV vaccine development. *Immunol. Rev.* 275:145-160, doi:10.1111/imr.12509 (2017)
- [12] Pater, A. A. et al. Emergence and Evolution of a Prevalent New SARS-CoV-2 Variant in the United States. *bioRxiv* doi:10.1101/2021.01.11.426287 (2021)
- [13] Andersen, K. G. et al. The proximal origin of SARS-CoV-2. *Nat. Med.* 26:450-452, doi:10.1038/s41591-020-0820-9 (2020)

Residue	AA	Orig	Broad	Epitope	ACE2	SialicAcid	Cleavage	Emerge
7	L	2	5	0				
12	S	1	5	0				
23	Q	2 *	4	0		1		
27	A	2	5	0				
33	T	1	5	2				
69	H	3 *	5	2		1		2
70	V	3 *	5	2		1		2
71	S	3 *	5	1				
72	G	2 *	3	1				
73	T	3 *	5	1				
74	N	3 *	6	1				
75	G	1	5	1				
76	T	3 *	7	2				
137	N	2	5	0				
147	K	2	5	4				
213	V	1	5	2				
218	Q	2 *	5	2				
224	E	1	5	0				
253	D	3 *	5	2				
255	S	2 *	5	1				
256	S	1 *	2	0				
272	P	2	5	0				
417	K	2 *	2	8	1			2
439	N	2 *	4	0				
440	N	2	5	0				
441	L	2 *	3	3				
444	K	2 *	3	0				
445	V	2 *	3	3				
449	Y	3	3	2	1			
450	N	2 *	5	11				
501	N	2 *	4	8	1			2
529	K	2 *	2	0				
532	N	2	5	0				
554	E	2 *	4	0				
556	N	2	5	0				
640	S	2	6	0				
677	Q	2 *	4	0				
679	N	2 *	5	0				
680	S	2 *	4	0				
684	A	3	1	0			1	
688	A	2	5	0				
689	S	2 *	3	0				

Table 1: High diversity residues. The most diverse residue positions are listed, along with several annotations. Orig, $diversity(outgroup-original)$; *, (nonsynonymous substitutions) / (synonymous substitutions) > 1 in outgroup-original; Broad, $diversity(outgroup-broad)$; Epitope, epitope frequency. See the caption of Figure 1. ACE2, residue is within 6Å of ACE2 in PDB entry 7DF4; SialicAcid, reported sialic acid binding residue [9]; Cleavage, known protease cleavage site; Emerge, frequency of mutations in emerging variants or human/mink transmitted lineage. See <https://mafft.cbrc.jp/alignment/pub/sarscov2/fulllist.tsv> for a full list.

Figures



E.

<i>diversity(outgroup-original)</i> (A)	1	2	3	
No. sites	1179	85	9	
No. mutated sites in emerging variants (green or red in C)	15	4	2	$p = 0.00099$
No. mutated sites in multiple emerging variants (red in C)	0	3	2	$p = 1.5 \times 10^{-7}$

F.

<i>diversity(outgroup-broad)</i> (B)	1	2	3	4	5	6	7	
No. sites	822	242	126	57	23	2	1	
No. mutated sites in emerging variants (green or red in C)	8	3	6	2	2	0	0	$p = 0.0057$
No. mutated sites in multiple emerging variants (red in C)	0	1	1	1	2	0	0	$p = 0.00046$

Figure 1

Diversity of the the S protein. For clarity, a single S protein is shown in the context of a spike trimer. A, B. *diversity(outgroup)*, the number of different amino acids observed at each site in outgroup, was computed using the original and broad definitions of outgroup: Low diversity (blue); High diversity (red). C. Emerging mutations are colored based on their frequency of appearance: 1 (green); 2 (red). D. Epitope frequency, the number of antibodies that contact each residue ($<6\text{\AA}$), was counted based on currently available Protein DataBank (PDB) entries of S protein-antibody complexes listed in <https://mafft.cbrc.jp/alignment/pub/sarscov2/epitopefrequency.txt>. 0 (blue); 15 (red). This value is not expected to represent all spike-targeting antibodies. E. Correspondence between *diversity(outgroup-original)* (A) and emerging mutations (C). F. Correspondence between *diversity(outgroup-broad)* (B) and emerging mutations (C). p values were calculated by Fisher's exact test under the null hypothesis that *diversity(outgroup)* (A or B) and distribution of emerging mutations (C) are independent of each other.